MARATTO

article · South African Medical Journal

Missed rifampicin and isoniazid resistance by commercial molecular assays

20241 citationOpen accessUniversity of the Witwatersrand

Abstract

Drug-resistant tuberculosis (TB) has poor outcomes unless resistance is detected early, ideally by commercially available molecular tests. We present a case of occult multidrug-resistant TB where both rifampicin and isoniazid resistance were missed by molecular testing and were only identified by phenotypic testing.

Research topics

  • Tuberculosis Research and Epidemiology
  • Mycobacterium research and diagnosis
  • Cancer therapeutics and mechanisms

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.7196/samj.2024.v114i17.1779

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.